You are viewing the site in preview mode
Skip to main content
|
Characteristic
|
Total = 3019
|
Discontinued = 351
|
Continued = 2668
|
P
|
|---|
|
N (%)
|
N (%)
|
N (%)
|
|---|
|
Gender
|
.083
|
|
Male
|
2605 (86.3)
|
292 (83.2)
|
2313 (86.7)
| |
|
Female
|
414 (13.7)
|
59 (16.8)
|
355 (13.3)
| |
|
Age (years)
|
.021
|
|
≤ 45
|
2240 (75.0)
|
244 (69.9)
|
1996 (75.7)
| |
|
> 45
|
746 (25.0)
|
105 (30.1)
|
641 (24.3)
| |
|
Mode of transmission
|
.598
|
|
MSM/Bisexual
|
1038 (34.4)
|
115 (32.8)
|
923 (34.6)
| |
|
Heterosexual
|
1683 (55.7)
|
198 (56.4)
|
1485 (55.7)
| |
|
IDU
|
6 (0.2)
|
1 (0.3)
|
5 (0.2)
| |
|
Other
|
62 (2.1)
|
11 (3.1)
|
51 (1.9)
| |
|
Unknown
|
230 (7.6)
|
26 (7.4)
|
204 (7.6)
| |
|
Pretreatment CD4 cell count (cells/mm3)
|
.011
|
|
< 200
|
723 (25.6)
|
104 (31.4)
|
619 (24.8)
| |
|
≥ 200
|
2103 (74.4)
|
227 (68.6)
|
1876 (75.2)
| |
|
Pretreatment viral load (copies/mL)
|
.213
|
|
< 100,000
|
1262 (45.0)
|
135 (41.7)
|
1127 (45.4)
| |
|
≥ 100,000
|
1545 (55.0)
|
189 (58.3)
|
1356 (54.6)
| |
|
AIDS diagnosis
|
.006
|
|
Yes
|
793 (26.3)
|
114 (32.5)
|
679 (25.4)
| |
|
No
|
2226 (73.7)
|
237 (67.5)
|
1989 (74.6)
| |
|
ART regimen type
|
<.001
|
|
InSTI
|
1135 (37.6)
|
63 (17.9)
|
1072 (40.2)
| |
|
InSTI/PI
|
6 (0.2)
|
1 (0.3)
|
5 (0.2)
| |
|
NNRTI
|
798 (26.4)
|
109 (31.1)
|
689 (25.8)
| |
|
PI
|
1080 (35.8)
|
178 (50.7)
|
902 (33.8)
| |
|
Type of initial ART
|
<.001
|
|
EFV/TDF/FTC
|
750 (24.8)
|
101 (28.8)
|
649 (24.3)
| |
|
LPV/r/TDF/FTC
|
743 (24.6)
|
121 (34.5)
|
622 (23.3)
| |
|
EVG/c/TDF/FTC
|
680 (22.5)
|
39 (11.1)
|
641 (24.0)
| |
|
DTG/TDF/FTC
|
351 (11.6)
|
10 (2.8)
|
341 (12.8)
| |
|
DRV/r/TDF/FTC
|
276 (9.1)
|
34 (9.7)
|
242 (9.1)
| |
|
RAL/TDF/FTC
|
65 (2.2)
|
12 (3.4)
|
53 (2.0)
| |
|
LPV/r/ZDV/3TC
|
53 (1.8)
|
21 (6.0)
|
32 (1.2)
| |
|
EFV/ZDV/3TC
|
39 (1.3)
|
7 (2.0)
|
32 (1.2)
| |
|
Other
|
62 (2.1)
|
6 (1.7)
|
56 (2.1)
| |
|
Year of ART initiation
|
.031
|
|
2011–2014
|
1495 (49.5)
|
193 (55.0)
|
1302 (48.8)
| |
|
2015–2017 Feb
|
1524 (50.5)
|
158 (45.0)
|
1366 (51.2)
| |
- Missing values: 6% for CD4 cell counts, 7% for pretreatment viral load
- 3TC lamivudine, DRV darunavir, DTG dolutegravir, EFV efavirenz, EVG/c elvitegravir/cobicistat, FTC emtricitabine, InSTI integrase strand transfer inhibitor, IDU injection drug user, LPV lopinavir, MSM men who have sex with men, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, RAL raltegravir, r ritonavir, TDF tenofovir disoproxil fumarate, ZDV zidovudine
